Athonis is an Australian preclinical drug discovery and health technology company focused on finding new therapies and pathways for unmet neurodevelopmental and neuropsychiatric conditions.
Athonis Therapeutics is developing novel small molecule therapeutics for autism spectrum disorder and related neurodevelopmental and neuropsychiatric conditions. There are no approved pharmacological treatments for the indications in our preclinical pipeline.
Athonis holds a patent pending on a novel combination of small molecule compounds covering four distinct indications. The compounds each have established preclinical or clinical safety profiles, reducing first-in-human risk associated with novel drug development.
Athonis will shortly commence its first preclinical study evaluating the novel combination in a validated model, with the potential to demonstrate disease modification rather than purely symptomatic improvement.
Earlier clarity for parents. Better outcomes for children.
Athonis's patent-pending digital platform differs from static quizzes. The eScreener sits at the intersection of early childhood development, autism, and support-needs identification — informed by clinicians, researchers, and parents.
Unlike traditional autism screeners, the eScreener classifies the likely intensity of developmental support a child may need, generating a structured output that maps to the language used by clinicians, early intervention services, and support frameworks including the NDIS.
Find out what support your child may need — and what to do next.
We believe that earlier identification of a child's developmental support needs leads to better outcomes for children and families. Our tools are designed to support those conversations, not replace clinical judgement.
Developed with clinical input, developmental research, and real parent feedback.
Designed for parents and primary health practitioners — no clinical administration required.
Outputs structured next-step guidance, not just a score — supporting navigation of health and support systems.
A patent-pending, computer-implemented developmental support-classification tool designed for parents of toddlers aged 18–36 months who have questions about their child's development or support needs. The eScreener is not intended to replace clinical assessment but to support it.
Athonis is developing an Enterprise Edition of the eScreener designed for federal and state government agencies, local health districts, maternal and child health services, early childhood intervention providers, paediatricians, and healthcare providers.
Building on the parent-facing platform, the Enterprise Edition will provide a centralised administrative dashboard, population-level reporting and analytics, and interoperability with existing state and federal health infrastructure including My Health Record.
The Enterprise Edition is being designed with public sector requirements in mind — including data sovereignty, Privacy Act 1988 compliance, and alignment with Australian government security frameworks. Athonis welcomes conversations with agencies interested in shaping the Enterprise roadmap or participating in a structured pilot program.
Athonis is advancing a novel small molecule combination across four neurodevelopmental and neuropsychiatric indications, united by a common validated biological pathway.
| Indication | Designation | Status |
|---|---|---|
| Autism Spectrum Disorder | Lead programme | Pharmacology study planned |
| Rare Paediatric Indication 1 | Orphan / PRV eligible | Shared pathway confirmed |
| Rare Paediatric Indication 2 | Orphan / PRV eligible | Shared pathway confirmed |
| Neuropsychiatric Indication | Pipeline extension | Mechanistic relevance established |
Athonis's lead programme targets autism spectrum disorder that affects 62 million individuals globally. Despite decades of research, no drug has received regulatory approval for the core symptoms of ASD. Athonis is advancing a novel small molecule combination toward a preclinical pharmacology study in a validated model, with endpoints mapping directly to outcome measures used in human ASD clinical trials. The programme is designed with the potential for disease modification, not purely symptomatic improvement, as a primary objective. Positive preclinical data will support progression toward a Phase 1b/2a clinical study in paediatric patients.
Two of Athonis's four indications are rare paediatric genetic disorders with no approved pharmacological treatments. They both share the same downstream biological pathway targeted by the Athonis compounds. Each qualifies for Orphan Drug Designation and Rare Pediatric Disease Designation from the US FDA, making each eligible for a Priority Review Voucher (PRV) on approval. A PRV grants the holder accelerated FDA review of any future drug application and is fully transferable. PRV eligible approvals from a single patent family would represent a significant potential value event for Athonis.
Athonis's fourth indication addresses a major unmet need in neuropsychiatry where the negative symptom burden remains almost entirely untreated by existing pharmacotherapy. The same biological pathway targeted by the Athonis combination has established mechanistic relevance to this indication through published human genetics and preclinical data. Athonis intends to pursue this indication as a pipeline extension.
Athonis is an Australian preclinical drug discovery and health technology company focused on finding new therapies and pathways for unmet neurodevelopmental and neuropsychiatric conditions.
We bring together expertise in drug development, clinical research, and digital health to address neurodevelopmental and neuropsychiatric conditions where effective treatments remain limited or absent.
Whether you are a clinician, health service, government department or agency, researcher, media or parent — we welcome enquiries about the eScreener, pilot programs, partnerships, or our therapeutics.